In:
Science Translational Medicine, American Association for the Advancement of Science (AAAS), Vol. 15, No. 716 ( 2023-10-04)
Abstract:
Diffuse gliomas are the most common primary brain tumors in adults, and the underlying molecular mechanism of its evolution is unknown. To shed light on this, Mu et al . collected 544 matching initial and recurrent samples from patients with diffuse glioma and performed whole-genome sequencing to evaluate correlations to progression. They identified that MYC gain or activation at diagnosis correlated to the worst patient prognosis and was able to drive temozolomide resistance in vitro. These data provide a resource that can lead to potential targets for therapy to overcome these therapeutic limitations in diffuse gliomas. —Dorothy Hallberg
Type of Medium:
Online Resource
ISSN:
1946-6234
,
1946-6242
DOI:
10.1126/scitranslmed.adh4181
Language:
English
Publisher:
American Association for the Advancement of Science (AAAS)
Publication Date:
2023